Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus cisplatin versus cisplatin alone in recurrent or metastatic head and neck cancer
2006-003158-12Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Pemetrexed + cisplatin with Cisplatin monotherapy (2 arms). Primary endpoint: Overall survival. Started Aug 2006; status: completed.
02
Drugs
pemetrexedcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-003158-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003158-12.